Changes observed in the MDM2-p53 pathway may provide a more effective and accurate way to diagnose early-stage HCC, allowing patients to undergo surgical resection earlier and significantly improving clinical outcomes in the absence of novel targeted treatments for this pathway. The gene discussed is TP53; the disease is hepatocellular carcinoma.